Join our mailing list
Get exclusive deals and learn about new products!
Reliable shipping
Flexible returns
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Published by: Springer
Publication Date: 2019-02-02
Format: Paperback
ISBN-13: 9783030098179
DOI: 10.1007/978-3-319-67932-7
Dimensions: 235cm x155cm
Pages: 242